NEW DELHI: Torrent Pharma, flagship of the Ahmedabad based Torrent Group, plans to drive growth by focusing on innovation to address “unmet needs in chronic therapies” and by expanding into highgrowth segments. The company, which holds market leadership in the vitamins category with its Rs 500-crore brand Shelcal (plus variants), and has cardiac drug Nikoran with sales of Rs 245-crore in its portfolio, will continue to build on these core strengths to sustain its growth trajectory, while foraying into newer segments, including the weightloss therapies.Besides India, Brazil is tipped to become its biggest market, even as the company is open to explore manufacturing opportunities in the US if it offers “long-term strategic value”, Aman Mehta, managing director of the over Rs 11,500-crore company, told TOI .Excerpts:It’s been an eventful year for you with one of the biggest acquisitions.